Seeking Alpha

UK regulators balk at price of Alexion's Soliris

  • Alexion Pharmaceuticals (ALXN) waits for approval to sell its blockbuster drug Soliris in the UK.
  • The National Institute for Health and Clinical Excellence (NICE) wants to examine the company's R&D costs for the drug to help it determine the appropriate reimbursement, considering its high cost.
  • Soliris is the most expensive drug in the world. Annual treatment cost runs £340,000 (US$569,000).
  • NICE's evaluation of the cost/benefits of the product falls under its new "ultra orphan" disease treatment review process. For Soliris, it has taken three years with no end in sight.
  • There are ~170 patients in the UK that would be eligible for Soliris, representing a cost to the National Health Service of 58M Pounds ($97M).
  • Soliris sales were $1.6B last year, with a forecast of $3.4B by 2018.
Comments (1)
  • Stkpicr
    , contributor
    Comments (8) | Send Message
     
    Once they get the okay this stock is off to the races. I do not think that the price targets of $195-210 is even close to where this stock will go. I honestly can see this one heading to $240+ by year end if not sooner.
    4 Mar, 11:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|